文献速递膀胱癌与上尿路尿路上皮癌

膀胱EpiCheck预测非肌层浸润性膀胱癌BCG应答的临床效用

Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2025-03-06

前瞻性研究纳入65例2018至2021年接受BCG治疗的非肌层浸润性膀胱癌患者,BCG诱导前后采集尿液行膀胱EpiCheck检测。BCG后EpiCheck结果、膀胱镜所见及EpiScore变化与肿瘤复发/BCG失败显著相关,含三变量的列线图预测任何膀胱癌事件的AUC为95.1%,优于CUETO风险表的67.1%。

要点

  • BCG后EpiCheck结果与肿瘤复发(OR 16.9,P<0.001)及BCG失败(OR 33.1,P<0.001)显著相关。
  • 含BCG后膀胱镜、BCG后EpiCheck及EpiScore变化的列线图预测任何膀胱癌事件AUC 95.1%,优于CUETO风险表67.1%。
  • BCG后EpiCheck状态及EpiScore变化有助于及时识别任何膀胱癌事件和BCG失败的高危患者。

核心结论

  • BCG后膀胱EpiCheck状态及EpiScore值变化可帮助及时识别任何膀胱癌事件和BCG失败风险较高的患者,这些数据可能影响疾病管理。

研究设计与样本

  • 前瞻性研究纳入65例2018至2021年间接受BCG治疗的非肌层浸润性膀胱癌患者,BCG诱导前后采集尿液行膀胱EpiCheck检测。
  • 采用二元逻辑回归评估临床和病理变量及EpiCheck结果与诱导治疗后第一年内肿瘤复发和BCG失败的关联。

主要发现

  • 随访期间16例(24.6%)患者发生膀胱癌事件,其中11例(68.8%)为BCG失败(高级别复发),5例(31.2%)为低级别复发。
  • 至总体复发的中位(范围)时间为7.3(3.8-17.4)个月。
  • 肿瘤复发/BCG失败风险与BCG后膀胱镜所见显著相关(分别为OR 10.0,P<0.001和OR 13.1,P<0.001)。
  • 肿瘤复发/BCG失败风险与BCG后EpiCheck结果显著相关(分别为OR 16.9,P<0.001和OR 33.1,P<0.001)。
  • 肿瘤复发/BCG失败风险与BCG前后EpiScore值变化显著相关(分别为OR 14.4,P=0.001和OR 7.1,P=0.018)。

关键数值与推荐

  • 含BCG后膀胱镜、BCG后EpiCheck结果及BCG前后EpiScore值变化三个变量的列线图预测BCG诱导后任何膀胱癌事件的AUC为95.1%,CUETO风险表为67.1%。

临床怎么用

  • BCG后EpiCheck状态及EpiScore值变化可帮助及时识别任何膀胱癌事件和BCG失败风险较高的患者,这些数据可能影响疾病管理。

局限性

  • 结果需要在更大且独立的系列中进行验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the performance of Bladder Epicheck® (BE; Nucleix Ltd., Rehovot, Israel) in predicting tumour recurrence and bacillus Calmette-Guérin (BCG) failure during the first year after induction treatment. PATIENTS AND METHODS: Prospective study including 65 patients with non-muscle-invasive bladder cancer treated with BCG between 2018 and 2021. Urine samples analysed with BE were collected before and after BCG induction. Logistic binary regression was used to assess the association between clinical and pathological variables and BE results with tumour recurrence and BCG failure during the first year after induction treatment. RESULTS: During follow-up, 16 (24.6%) patients experienced a bladder cancer event, 11 (68.8%) of which were BCG failure (high-grade recurrence) and five (31.2%) were low-grade recurrences. The median (range) time to overall recurrence was 7.3 (3.8-17.4) months. A significant association was found between the risk of tumour recurrence/BCG failure and post-BCG cystoscopy (odds ratio [OR] 10.0; P < 0.001 and OR 13.1; P < 0.001, respectively), post-BCG BE result (OR 16.9; P < 0.001 and OR 33.1; P < 0.001, respectively) and pre/post-BCG EpiScore value variation (OR 14.4; P = 0.001 and OR 7.1; P = 0.018, respectively). A nomogram including these three variables outperformed the Club Urológico Español de Tratamiento Oncológico (CUETO) risk tables to predict any bladder cancer event after BCG induction (area under the curve 95.1% vs 67.1%). Result validation in a larger and independent series is needed. CONCLUSIONS: The BE post-BCG status and variations in EpiScore values can help us identify patients at higher risk of any bladder cancer event and BCG failure promptly. These data can have an impact on disease management.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Roldán FL, Ingelmo-Torres M, Mercader C, et al. Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer. BJU Int. 2025. PMID: 40047306. doi:10.1111/bju.16697

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。